A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic dermatitis.
The estimated duration is 28 days for screening and then up to approximately day 477 (last dose no later than day 337+140 days safety follow-up) for all patients unless enrolled into the Long-Term Extension (LTE) protocol (NCT05492578) at either Day 169 depending on responder status or no later than Day 365 due to loss of clinical response.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Nový Jicín, Moravian-Silesian Region 741 01, Czechia
Obihiro-Shi, Hokkaidô 080-0013, Japan
Adachi-Ku, Tokyo 120-0034, Japan
Chuo Ku, Tokyo, Japan
Edagowa-Ku, Tokyo 133-0052, Japan
Koto-Ku, Tokyo 136-0074, Japan
Minato-Ku, Tokyo 108-0014, Japan
Setagaya-Ku, Tokyo 158-0097, Japan
Mibu-machi, 321-0293, Japan
Habikino-Shi, Ôsaka 583-0872, Japan
Lódz, Lódzkie 90-127, Poland
Niao Song Qu, 833, Taiwan